NCT06662812Completed
Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry
Disease Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery (GRNDaD) Registry
Source: ClinicalTrials.gov · Last updated 29 Oct 2024
Brief summary (registry, in English)
This was a retrospective observational cohort study. This study was a secondary analysis of individuals with sickle cell disease (SCD) enrolled in the GRNDaD registry.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1665 (actual)
- First submitted
- 27 Oct 2024
- Start date
- 6 Oct 2021
- Primary completion date
- 1 Dec 2023
- Lead sponsor
- Novartis
- Diseases
- Sickle cell disease
- NCT number
- NCT06662812
What you commit to
- Study type: Observational
- Participants enrolled: 1665
- From 6 Oct 2021 to the primary completion date, 1 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None identified at this time.
Who the study is looking for
- Diagnosis of SCD.
- Signed consent to participate in GRNDaD registry.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Pharmaceuticals Coordinator of this site? Confirm its status | East Hanover | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.